Herpes simplex virus (HSV) can cause oral or genital ulcerative lesions and even encephalitis in various age groups with high infection rates. More seriously, HSV may lead to a wide range of recurrent diseases throughout a lifetime. No vaccines against HSV are currently available. The accumulated clinical research data for HSV vaccines reveal that the effects of HSV interacting with the host, especially the host immune system, may be important for the development of HSV vaccines. HSV vaccine development remains a major challenge. Thus, we focus on the research data regarding the interactions of HSV and host immune cells, including dendritic cells (DCs), innate lymphoid cells (ILCs), macrophages, and natural killer (NK) cells, and the related signal transduction pathways involved in immune evasion and cytokine production. The aim is to explore possible strategies to develop new effective HSV vaccines.
| INTRODUCTION
Herpes simplex virus (HSV) belongs to the alpha subfamily of the human herpesvirus family and includes HSV1 and HSV2, which are responsible for pandemics of various herpes diseases. 1 Both pathogens have similar structural characteristics and are of concern worldwide, not only because the clinical outcome of oral or genital ulcerative lesions has long-lasting impacts on patient quality of life but also because ocular herpes can lead to blindness, and neonatal herpes or encephalitis can result in higher death rates. [2] [3] [4] In addition, the viruses show higher infection rates in various age groups. 5 Although observations of epidemics in various areas have described different pandemics, infection rates of at least 30% to 60% for HSV1 and 10% to 25% for HSV2 have been recognized by most researchers, 6, 7 and approximately 23 million new cases of HSV2 infection are reported annually. 8 It is not surprising that a viral disease with such severe clinical outcomes and such a strong spreading trend has been targeted for prophylactic vaccine development. To date, more than 10 HSV prophylactic vaccines, mainly vaccines targeting HSV2, have been developed and evaluated in human clinical trials. 9, 10 These --------------------------------------------------------------------------------------------------------------------------------vaccines contain antigens that effectively stimulate immune responses and immune memory, as measured by the indicators of neutralizing antibody and specific cellular immune responses in animals or humans. 11, 12 These data suggest that the viral antigens selected and designed for vaccines are effective and that the host immune system is capable of recognizing HSV antigens. However, of the vaccines that have undergone evaluation in a clinical trial, none except a vaccine against HSV2 that showed only low efficacy for HSV1 infection but did not work against HSV2 infection has demonstrated sufficient efficacy for further development or commercialization (Table 1) . 11 On the basis of these results, we hypothesize that the evaluations currently used in HSV vaccine development, in which antiserum from immunized individuals blocks virus infection in cells in classic neutralizing antibody assays and antigenic peptides from viral surface molecules specifically induce the proliferation of interferon γ (IFN-γ) secreting T cells in enzyme-linked immunospot (Elispot) assays, might not fully and accurately represent an immune response that enables the control of HSV infection. Both classic assays show that neutralizing antibodies block virus entry into a single type of cell, usually epithelial cells or fibroblasts, 26 and Elispot assays reveal only the capacity to develop a CD4 or CD8 T-cell immune response to limited antigens mainly located on the viral surface. 27 Furthermore, it is reasonable to infer that the immunity induced naturally in most individuals infected by HSV might be incomplete or weakly effective on the basis of the observation that most infected individuals seem to be unable to clear the virus completely in their lifetime. 28 If this is the case, we must ask how the virus interacts with the immune system during its infectious process and leads to an abnormal immune response, which might produce specific antibodies against only viral surface proteins. The accumulated research data concerning the interactions of HSV and host cells and the associated pathogenic mechanisms can help us to answer this question. In these works, the HSV genome was revealed to possess a large amount of genetic information and a complicated transcription mechanism 29 and to encode various functional molecules, 30 which enable interactions with the cellular microenvironment in a systematic and sequential manner to facilitate pathogenesis. 31, 32 Although this process is basically similar to that of some RNA viruses with simple structures that expose their inner pathogen-associated molecule patterns (PAMPs) to cellular pattern recognition receptors (PRRs) in infected cells and activate the NF-κB transcription pathway of innate immunity, 33 HSV possesses various encoded molecules that are not only recognized by PRRs but also used to block or regulate the PRR signal transduction pathways that activate NF-κB. [34] [35] [36] This feature might be predicted to lead to a deviation in signal transduction during the innate immune response, which usually involves the activation of innate immune cells, including dendritic cells (DCs), innate lymphoid cells (ILCs), macrophages, and natural killer (NK) cells. [37] [38] [39] This activation can be understood as a broader response than the immune response elicited during HSV infection, which appears to produce specific humoral and cellular responses against only viral surface structures recognized by the innate immune system during the early stages of infection. Our previous understanding of HSV vaccination depended on the observation of clinical immunological data from viral infection or disease and might not support the development of a new generation of HSV vaccines. Further analysis of the mechanism by which HSV interacts with the host and the pathogenic effects of HSV on the immune system will be helpful for our efforts to develop HSV vaccines. In this review, we discuss the available data concerning 14 Mutated with the gK and UL20 * HSV2 △NLS 15 HSV2 ICP0virus, 0ΔNLS * HSV2 △gD2 16 Deleted in gD * AD472 17 Deleted both copies of the γ134.5, UL55-56, UL43.5, and the US10-12 region * Subunit vaccine HSV2 gD 12 gD with alum and 3-O-deacylated monophosphoryl lipid A * HSV2 gB/gD/MF59 18 gB and gD with MF59 * HSV1 VP11/12 19 VP11/12 [66] [67] [68] [69] [70] [71] [72] [73] [74] , VP11/12 220-228 , and VP11/12 702-710 * Replication-defective HSV2 529 20 Deleted in UL5 and UL29 * HSV1 d120 21 Deleted in ICP4 * HSV1 d92 21 Deleted in ICP4 and ICP27 * HSV1 d95 21 Deleted in ICP4, ICP27, and ICP22 * HSV1 d97 21 Deleted in ICP4, ICP27, and ICP0 * HSV1 vhs − /ICP8 −22
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| THE STRUCTURAL CHARACTERISTICS OF HSV DETERMINE ITS STRATEGY FOR INTERFERING WITH HOST DEFENSE
A previous description of HSV indicated that the genomic lengths of the virus types were 152 201 bp for HSV1 (strain McKrae) 40 and 154 746 bp for HSV2 (strain HG52), 41 and these genomes could encode at least 80 proteins, in addition to some RNA molecules.
Among these proteins, approximately 20% were found to directly support viral replication, 42 12% were immunogenic surface glycoproteins, 43 and more than 50% were involved in interactions with the host and indirectly supported virus survival in vivo. 44 The existence of these kinds of protein in HSV, which has coevolved with humans for a long time, suggests not only that viral pathogenesis involves various interactions of viral molecules with different cells and tissues 45 but also that the virus uses strategies to activate cellular transcription and evade immune monitoring to create an effective environment for viral proliferation. 46 It could be proposed that immune pressure from the host has pushed HSV to fully exploit its genomic evolution by encoding a series of functional molecules and gradually creating different pathways for blocking or weakening innate and adaptive immunity during the continuous interplay between viruses and humans. 28, 47 Of note, a recently published paper indicates that the HSV1 0ΔNLS vaccine elicits antibody responses against heterogeneous viral proteins, including nonstructural proteins. 48 However, to some extent, the characterized patho- 
| Interaction of HSV surface glycoproteins with cellular receptors
As an enveloped DNA virus, HSV possesses several typical envelope glycoproteins, 43 which play roles in binding to cellular surface receptors and mediating virus entry into cells. 49 A total of 12 glycoproteins have been found in the viral envelope, and at least five glycoproteins, gB, gC, gD, gH, and gL, have been demonstrated to enable interactions with cellular receptors to promote virus entry. 50 Reported data have suggested that gB can bind to heparin sulfate (HS) on the cell surface and couple to paired immunoglobulin-like type 2 a receptor (PILR) 51 and that gC is also involved in these interactions. 52, 53 Interestingly, after gB binds to its receptor, gD is induced to interact with nectin-1 and poliovirus-receptor-like (PVRL1) on epithelial cells or herpes virus entry mediator (HVEM or TNFRSF14) on immune cells, 54 as gD can interact with HS. 55 The binding of gD to receptors also causes the activation of gH/gL and the formation of a complex containing both glycoproteins, 56 followed by increased fusion of the viral and cellular membranes mediated by gB. 57, 58 During this process, gC can promote virus entry into cells through binding to cellular proteins. 59 There are also data suggesting that gH/gL plays a more important role in the fusion of viral and cellular membranes and that cellular integrin is a potential receptor for gH/gL. 60 Endocytic vesicles are also a pathway of viral entry into cells. 61 These data suggest that HSV uses a more systematic strategy for entry into cells than most viruses. This strategy involves various surface glycoproteins interacting with different cellular receptors. This process implies that the basic idea of blocking virus entry into cells requires a combination of multiple neutralizing antibodies rather than a few antibodies. Furthermore, the recognition of HVEM by gD leads to viral tropism for various innate immune cells expressing HVEM, including DCs, ILCs, macrophages, NK cells, and even CD8 cytotoxic T cells. [62] [63] [64] [65] Thus, HSV is capable of infecting these cells in epithelial tissue after proliferating in epithelial cells and inducing the innate immune response ( Figure 1 ). 33 In light of this evidence, it is reasonable to speculate that the innate immune cells that function in phagocytosis, antigen presentation, and the transfer of stimulatory signals are hijacked and probably adopt a heterogeneous phenotype, leading to the transfer of a heterogeneous signal for the stimulation of adaptive immunity.
| Biological features and potential immunogenicity of the HSV tegument
Among the HSV structural components, tegument proteins are functional molecules that are located between the viral capsid enveloping the genome and the outer membrane. 66, 67 To date, approximately 24 tegument proteins have been identified and found to play important roles in viral structure, 68, 69 as they provide supportive functions for establishing an effective microenvironment for viral proliferation during infection. 70, 71 Previous reports indicated that the genes encoding seven tegument proteins are conserved between HSV1 and HSV2 and possess high similarity in viruses in the alpha subfamily, 72 suggesting important roles for these proteins in viral evolution.
Most tegument proteins form complex structures by interacting with each other and anchoring to capsids or membranes to stabilize the viral structure. [73] [74] [75] Topological data suggest that the interactions between tegument proteins and cellular structure may or may not depend upon the myristyl-and palmityl-base anchors produced by posttranslational modifications on the surfaces of these proteins. 76, 77 Interestingly, some tegument proteins play important roles through their interactions with cellular molecules, as they are involved in the viral structural network. 68, 73 Typically, the tegument proteins Vp16
and Vhs, which are encoded by the ul48 and ul41 genes, respectively, can form a trimeric complex with another tegument protein encoded by ul49 (pUL49-pUL48-pUL41). 78, 79 Furthermore, VP16 is thought to reside closer to the viral envelope and be part of the outer tegument. VP16 also plays an important role in viral egress downstream of the initial envelopment step. 80 VP16 is also capable of participating in a supporting structure (pUL36-pUL37-pUL48) with two tegument proteins encoded by the ul36 and ul37 genes. 81 However, most investigations of VP16 and Vhs have focused on their biological functions in regulating the transcription of the viral genome and interfering with host RNA synthesis, respectively. 82 VP16 was found to interact with the cellular transcripts octamer-binding transcription factor 1 (Oct-1) and host cell factor 1 (HCF-1) and to initiate transcription of the viral α-gene via a three-component complex, which controls viral proliferation in cells, probably including neurons. 83, 84 Vhs plays roles in interfering with host RNA synthesis and providing a space for transcription during viral proliferation. 85, 86 Studies have suggested the biological and pathological significance of tegument proteins in viral structure and infection. Importantly, the findings of these studies have also implied that if tegument proteins were recognized by the immune system during infection, the pathological effects of the virus could be limited to some extent; the deletion of some tegument proteins could also be a way to influence viral pathogenesis. A study of the tegument protein UL7 suggested similar results, as the UL7-UL51 complex was found to colocalize with gE in the nuclear region of infected cells. 87 The deletion of the ul7 gene eliminates this colocalization but does not affect viral structural. 88, 89 Interestingly, partial deletion of this gene could limit viral proliferation and lead to delayed growth kinetics of the virus in cultured cells or animals because UL7 regulates the transcription of the viral α-gene, 90 and this partial deletion could provide an attenuated viral phenotype (Figure 1 ). 91 Other studies have also suggested that VP22, which is encoded by the ul49 gene, is capable of interacting with cellular cGAS and inhibiting its enzymatic activity, as VP22 functions in the viral structural network. 70 The tegument proteins encoded by ul16 and ul46 also show capacities to interact with cellular mitochondria and p85, growth factor receptor bound protein 2 (Grb2), and shc of the Src-family kinases, respectively, as part of their roles in the viral structural network. 92, 93 These data describe a specific context for HSV infection, in which the viral strategy is to present only surface glycoproteins to the immune system, as most of the pathogenic viral molecules work within infected cells and can avoid monitoring by the innate and adaptive immune systems through various forms of immune evasion.
| THE STRATEGY BY WHICH HSV EVADES MONITORING BY THE IMMUNE SYSTEM
Observations from epidemics of HSV infection worldwide suggest a characteristic clinical feature in which a high ratio of serum positivity,
FIGURE 1
Interactions of herpes simplex virus (HSV) surface glycoproteins and tegument proteins with cellular components to interfere with host defense. At least five glycoproteins, gB, gC, gD, gH, and gL, have been demonstrated to enable interactions with epithelial cellular receptors or immune cells to promote virus entry or proliferation or even to disrupt innate and adaptive immunity. In addition, some tegument proteins play important roles, for example, roles in viral proliferation, viral virulence, and host immunity evasion, through interacting with cellular molecules which reaches more than 50% in the population, is associated with viral latency in the nervous system, which can lead to viral reactivation in infected individuals. 7 This process has been demonstrated to be caused by the latent infection of neurons by HSV. 30 On the basis of data from studies of HSV pathogenesis, this conclusion is reasonable.
The only uncertainty is whether viral latency, which depends on the process of viral entry into neurons from epithelial tissue, might lose control of the activated innate immune response during viral infection or still retain control because of the strong neurotropic characteristic of HSV. 94, 95 Although there are many examples of neurotropic viruses that have the characteristics of intense neurotropism and a shorter proliferative cycle than HSV, a lower rate of neuron infection was observed for these viruses than for HSV. 96 In contrast, neuron infection by HSV is observed in 100% of virus-infected individuals. Thus, it is logical to infer that HSV possesses the capability to interfere with innate immunity, as innate immunity is activated by viral infection in the epithelial tissue of infected individuals. 97 an immune evasion strategy 98 and is probably due to viral interference with the immune system by various encoded viral proteins. 99 To understand this process, it is necessary to review the details of the interactions between the virus and the innate and adaptive immune systems. and promoting the enzymatic proteolysis of p50, which possesses a function similar to that of p65. 108, 109 On the other hand, ICP0 was found to be capable of interacting with the IFI16 protein and downregulating its phosphorylation to assist cGAS in sensing viral doublestranded DNA (dsDNA) during viral genomic replication, which could interfere with signal transduction in the IFN pathway. 110 The HSV tegument protein Us3 was observed to inhibit the activation of NF-κB by superphosphorylating p65 in virus-infected cells and to block the translocation of superphosphorylated IRF-3 into the nucleus, which could directly inhibit IFN production. 111 This process could be involved in the variations in either inflammatory factors and/or chemokines during HSV infection. 112 Other virus-encoded proteins, such as ICP27, enable the inhibition of NF-κB by interacting with IκBα, 113 and UL42 inhibits NF-κB activity by interacting with the p65/50 complex and retaining this complex in the cytoplasm. 114 The tegument protein VP16 interacts with p65 and represses NF-κB while interfering with the binding of CREB to the IRF-3 complex to block the IRF-3 transcriptional process. 115 Another tegument protein, Vhs, binds to the mRNAs of IFNstimulated genes to promote their degradation and leads to reduced antiviral activity of IFN members. 85 An important viral protein, γ-34.5, targets TBK1 to block its interaction with IRF-3 and repress IFN production, 116 and viral VP24 interacts with both TBK1 and IRF-3 to block signal transduction and repress IFN expression. 117 These observations provide extensive evidence that HSV interferes with IFN production (Figure 2 ). These data demonstrated that an innate response that relies on IFN might not restrain the neurotropic spread of HSV from primary infected epithelial tissues to neurons. It should be stressed that various immune signals, such as tumor necrosis factor (TNF) members and cytokines including interleukins (IL-1, IL-4, IL-13, IL-17, IL-22, and IL-33), which could play important roles in the activation of various innate immune cells and are regulated by the NF-κB transcription system, are equally crucial for IFN production. [118] [119] [120] Thus, the signaling network that activates and regulates processes in the innate immune system during the initial response to HSV infection can be disrupted by virus-encoded molecules.
| HSV infection and the IFN reaction of the host

| HSV and host apoptosis during infection
In mammals, apoptosis is capable of maintaining homeostasis in normal tissues, [121] [122] [123] which means that apoptosis is involved in defending against viral infection, as it is triggered by stimuli during lytic viral infection. 124 Apoptosis is involved in the disruption of mitochondrial membrane integrity, which releases cytochrome c into the cytoplasm. 125 Importantly, Bcl-family members, including Bcl-2, Bclw, Bcl-x L Bax, Bak, Bad, Bid, Bim, Bik, Noxa, and PUMA, exert proapoptotic or antiapoptotic effects to regulate and integrate this physiological process. [126] [127] [128] In theory, apoptosis should limit HSV proliferation in the cell nucleus, as this process requires more than 18 hours at the primary infection site during the early stage of infection. However, this innate defense mechanism does not effectively repress viral spread from infected epithelial cells to neurons or other tissues, even if apoptotic cells are detectable. 124 Previous data have suggested that the immune evasion strategy used by HSV during infection depends to some extent on its antiapoptotic mechanism. 129 Studies have shown that soluble viral gD activates the NF-κB, Akt, and ERK1/2 signaling pathways in macrophages and prevents apoptosis triggered by staurosporine. gD is also capable of preventing apoptosis in U937 cells triggered by anti-Fas antibodies. 130, 131 Further investigation has shown that this antiapoptotic effect of gD is associated with the upregulation of the expression of the Bcl-2 and Bcl-xl genes, which both encode antiapoptosis proteins, and downregulation of the expression of the Bcl-xs gene, which encodes a protein that promotes apoptosis. 132 The mechanism of this process might involve cellular cyclophilin, which is capable of triggering apoptosis, its receptor HS, and signaling pathways associated with the Akt and ERK1/2 complex. Interestingly, HS has been shown to be bound by viral gD.
Many studies have focused on the main apoptosis regulator of HSV during infection, the viral serine/threonine protease Us3, and found that the virus is capable of modulating the apoptotic process on the basis of its requirement for cell proliferation during infection. 133 Us3
can mediate the posttranslational modification of the Bad protein, which negatively regulates apoptosis through its kinase activity, and block protease A to activate some apoptotic signals via the prephosphorylation of protease A. 134 The data also suggest that Us3
can interact with the apoptosis-related protein programmed cell death 4 (PDCD4) to block the initiation of apoptosis in infected cells. 135 Us3 enables the attenuation of JNK activity, which assists with the activation of apoptotic signals in a state of cellular stress. 136 This capacity was confirmed in a study with a Us3-deficient strain. 137 On the other hand, the viral protein Us5, which is also named gJ, is encoded in a multigene open reading frame with Us3 and is capable of preventing apoptosis triggered by an anti-Fas antibody. 138 Interestingly, the viral immediate protein ICP27 is able to promote or inhibit apoptosis depending upon the infectious background. 139, 140 These data suggest that HSV possesses a set of mechanisms for regulating apoptosis to proliferate in primary infectious sites and spread to various tissues and cells, especially neurons; preventing or enhancing apoptosis could be part of this viral strategy. Importantly, host apoptosis works to control viral spread and initiate the phagocytosis of dead cells and viruses by the innate immune system, 141 which contributes to innate immunity and activates adaptive immunity. The HSV strategy for effectively regulating apoptosis might lead to abnormal progression from innate to adaptive immunity. to the major histocompatibility complex 1 (MHC-1) molecule in cells. 144 The data have also suggested that HSV is capable of interacting with caveolin-1 to alter the activity of nitric oxide synthase and limit the production of NO 145 and that the migration rate of infected DCs moving from the local tissue to the lymph nodes was decreased because of an increased death rate. 142 All of these data suggest the hypothesis that by interfering with DCs, a major antigen-presenting cell in In this sense, the specific immunity induced in HSV-infected individuals might be inferred to be a type of incomplete immunity.
| Infection of immune cells by HSV and the pathological significance
| CONCLUSION
| Tactics for HSV vaccine development
In recent decades, different types of HSV vaccines, including inactivated vaccines, peptide vaccines containing various antigenic structures, and replication-deficient vaccines, have been investigated To satisfy these biological requirements in a vaccine candidate, a complex antigenic structure or an attenuated strain integrated with mutated structural genes could be generated with molecular techniques. 
